BioPharmics LLC was founded in 1998 to develop algorithms and software for computational drug design. We have leading solutions in the areas of molecular docking, molecular similarity, off-target prediction, and binding affinity prediction. All methods within the Surflex platform couple physical realism in modeling protein-ligand interactions with algorithms for rapid optimization of conformation and alignment of small molecules. BioPharmics LLC has implemented efficient and unique solutions with state-of-the-art performance.
We are committed to public disclosure of our scientific methodology in peer-reviewed academic journals. We are also committed to the use of fair benchmark comparisons to facilitate technical progress in the field.